Roivant Sciences price target raised to $30 from $24 at Jefferies

Jefferies raised the firm’s price target on Roivant Sciences (ROIV) to $30 from $24 and keeps a Buy rating on the shares. Roivant reported “solid” Phase 2 cutaneous sarcoid data, which supports the firm’s thesis that brepocitinib “could eventually be ‘Rinvoq for rare diseases’ as indications stack over time,” the analyst tells investors.